Literature DB >> 1357006

HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

A H Arnaout1, P M Dawson, S Soomro, P Taylor, N A Theodorou, M Feldmann, B M Fendly, H M Shepard, S Shousha.   

Abstract

Paraffin wax sections of 70 surgically resected colorectal adenocarcinomas were examined for the overexpression of HER2/c-erbB-2 oncoprotein using three different specific antibodies and the avidin-biotin immunoperoxidase technique. The patients included 38 men and 32 women aged between 47 and 80 years. The tumours were derived from various parts of the large intestinal tract, and represented all three stages of Dukes' classification and the three histological grades of differentiation. Many tumour sections also included adjacent normal or transitional mucosa. Eight tubular adenomas found in the colectomy specimens in association with some carcinomas were also examined. No positive membrane staining was seen in any of the 70 carcinomas, four adenomas, two hyperplastic polyps, nor in the adjacent normal or transitional mucosa. It is suggested that the overexpression of c-erbB-2 gene product is unlikely to be as common and as pronounced in colorectal adenocarcinoma as it is in ductal carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357006      PMCID: PMC495156          DOI: 10.1136/jcp.45.8.726

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance.

Authors:  M Gutman; Y Ravia; D Assaf; T Yamamoto; R Rozin; Y Shiloh
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

2.  Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon.

Authors:  J D'Emilia; K Bulovas; K D'Ercole; B Wolf; G Steele; I C Summerhayes
Journal:  Oncogene       Date:  1989-10       Impact factor: 9.867

3.  c-erbB-2 oncoprotein expression in primary human tumors.

Authors:  A McCann; P A Dervan; P A Johnston; W J Gullick; D N Carney
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

4.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

Authors:  B M Fendly; M Winget; R M Hudziak; M T Lipari; M A Napier; A Ullrich
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

5.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.

Authors:  M Tal; M Wetzler; Z Josefberg; A Deutch; M Gutman; D Assaf; R Kris; Y Shiloh; D Givol; J Schlessinger
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

6.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

7.  Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.

Authors:  P G Natali; M R Nicotra; A Bigotti; I Venturo; D J Slamon; B M Fendly; A Ullrich
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

8.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

9.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.

Authors:  R A Walker; W J Gullick; J M Varley
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

10.  Oncoprotein stability after tumour resection.

Authors:  G Ong; W Gullick; K Sikora
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

  10 in total
  7 in total

1.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

2.  HER2/ERBB2 immunoreactivity in human retinoblastoma.

Authors:  G M Seigel; S Sharma; A S Hackam; Dhaval K Shah
Journal:  Tumour Biol       Date:  2015-11-27

3.  The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas.

Authors:  W Vogel; R Kath; H Kosmehl; E Olschowsky; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.

Authors:  Prema P Peethambaram; Michelle E Melisko; Kristine J Rinn; Steven R Alberts; Nicole M Provost; Lori A Jones; Robert B Sims; Lisa R C Lin; Mark W Frohlich; John W Park
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

5.  Allosteric autoactivation of SOS and its kinetic mechanism.

Authors:  Hanh My Hoang; Hope Gloria Umutesi; Jongyun Heo
Journal:  Small GTPases       Date:  2019-04-13

6.  In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina.

Authors:  Gail M Seigel; Dhaval K Shah; Pia Mendoza; Ezster Szalai; Hans Grossniklaus; Yinghui Song; Jidong Shan
Journal:  Oncoscience       Date:  2019-08-23

7.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Authors:  Erik J Blok; Peter Jk Kuppen; Jeroen Em van Leeuwen; Cornelis Fm Sier
Journal:  Clin Med Insights Oncol       Date:  2013-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.